Real-world treatment outcomes of carfilzomib plus dexamethasone in patients with relapsed and/or refractory multiple myeloma, focusing on the impact of trial-fitness: CAtholic REsearch network for Multiple Myeloma study (CAREMM-2203)-Reference-Cited by-同舟云学术

Real-world treatment outcomes of carfilzomib plus dexamethasone in patients with relapsed and/or refractory multiple myeloma, focusing on the impact of trial-fitness: CAtholic REsearch network for Multiple Myeloma study (CAREMM-2203)

Published:2023-09-12 Issue:18 Volume:149 Page:16279-16291
ISSN:0171-5216
Container-title:Journal of Cancer Research and Clinical Oncology
language:en
Short-container-title:J Cancer Res Clin Oncol

Author:

Park Sung-Soo,Goo Seo-Young,Jeon Young-Woo,Yhang Seung-Ah,Shin Seung-Hwan^ORCID,Min Chang-Ki

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s00432-023-05385-8.pdf

Reference22 articles.

1. Costa LJ, Hari PN, Kumar SK (2016) Differences between unselected patients and participants in multiple myeloma clinical trials in US: a threat to external validity. Leuk Lymphoma 57(12):2827–2832. https://doi.org/10.3109/10428194.2016.1170828

2. Del Giudice ML, Gozzetti A, Antonioli E, Attucci I, Pengue L, Cassano Cassano R, Ghio F, Orciuolo E, Simoncelli M, Bocchia M, Galimberti S, Buda G (2022) Carfilzomib plus dexamethasone in patients with relapsed and refractory multiple myeloma: a retro-prospective observational study. Eur J Haematol 109(4):373–380. https://doi.org/10.1111/ejh.13819

3. Dimopoulos MA, Moreau P, Palumbo A, Joshua D, Pour L, Hajek R, Facon T, Ludwig H, Oriol A, Goldschmidt H, Rosinol L, Straub J, Suvorov A, Araujo C, Rimashevskaya E, Pika T, Gaidano G, Weisel K, Goranova-Marinova V, Schwarer A, Minuk L, Masszi T, Karamanesht I, Offidani M, Hungria V, Spencer A, Orlowski RZ, Gillenwater HH, Mohamed N, Feng S, Chng WJ, Investigators E (2016) Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. Lancet Oncol 17(1):27–38. https://doi.org/10.1016/S1470-2045(15)00464-7

4. Jelinek T, Maisnar V, Pour L, Spicka I, Minarik J, Gregora E, Kessler P, Sykora M, Frankova H, Adamova D, Wrobel M, Mikula P, Jarkovsky J, Diels J, Gatopoulou X, Vesela S, Besson H, Brozova L, Ito T, Hajek R (2018) Adjusted comparison of daratumumab monotherapy versus real-world historical control data from the Czech Republic in heavily pretreated and highly refractory multiple myeloma patients. Curr Med Res Opin 34(5):775–783. https://doi.org/10.1080/03007995.2017.1410121

5. Kastritis E, Terpos E, Dimopoulos MA (2022) How I treat relapsed multiple myeloma. Blood 139(19):2904–2917. https://doi.org/10.1182/blood.2020008734